BEIJING, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company") which develops, assembles, markets and sells medical devices and wearable sleep respiratory products in China, today announced that twenty-eight medical examination centers and hospitals in China have introduced Dehaier's wearable sleep respiratory technology systems to provide Obstructive Sleep Apnea Syndrome ("OSAS") diagnosis, CPAP treatment, curative effect evaluation and other related services.
The first batch of customers are the sleep medical centers, respiratory departments, ENT departments and neurology departments from twenty-two hospitals and six medical examination centers located across China in Beijing, Shanghai, Tianjin, Henan, Shandong, Shanxi and Gansu provinces. Dehaier has implemented multiple system working stations, software, watch-sized sleep diagnostic devices and a number of PPG sensors to cater to the current OSAS diagnostic demand of the hospitals and medical examination centers. Dehaier hopes the wearable sleep respiratory technology systems used in these top-tier hospitals will serve as a platform for the Company's future market expansion.
Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical stated, "We are excited about this breakthrough for our respiratory business. After persistent efforts on R&D, CFDA certification and dedication to market activities for more than three years, we have successfully delivered our sleep respiratory systems to medical institutions. We believe that it will be an effective supplement to the traditional OSAS diagnosis in the medical field. We foresee that the application of this system will effectively increase outpatient volume for sleep monitoring and diagnosing and reduce purchasing costs associated with large-scale diagnosis equipment PSG. We also expect disposable PPG sensors will generate continuous cash flow for the Company. As for the patients, sleep respiratory diagnosis have been covered by national insurance and patients will be only charged for the affordable PPG sensor. Furthermore, patient waiting time, usually from three to six months, for hospital beds should be cut dramatically, as the system makes earlier diagnosis and treatment available."
Mr. Ping Chen added, "Choosing well-known top-tier hospitals for the early stage of market development should position us favorably to improve market share and expand throughout China. To ensure that the systems and products function well, we have set up a technical service crew to provide training and technical support for each hospital equipped with our systems. We are actively introducing our solutions to more hospitals' respiratory departments and any other departments where OSAS is diagnosed. In addition to expanding our landscape to equip more top-tier model hospitals nationwide, we also expect to cooperate with more top-level hospitals to capture the market."
About Dehaier Medical Systems Ltd.
Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including medical devices and wearable sleep respiratory products. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), HEYER (Germany) and Timesco (UK). Dehaier's technology is based on six patents and eleven software copyrights. More information may be found at http://www.dehaier.com.cn
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
CONTACT: Dehaier Medical Systems Limited +86 10-5166-0080 Janice Wang email@example.comSource:Dehaier Medical Systems Limited